{"classes":[{"categories":[{"measurements":[{"comment":"Upper CI not calculable due to insufficient number of events.","groupId":"OG000","lowerLimit":"10.8","upperLimit":"NA","value":"14.4"},{"comment":"Median and upper CI not calculable due to insufficient number of events.","groupId":"OG001","lowerLimit":"2.6","upperLimit":"NA","value":"NA"},{"comment":"Upper CI not calculable due to insufficient number of events.","groupId":"OG002","lowerLimit":"6.9","upperLimit":"NA","value":"10.6"},{"comment":"Median and CI not calculable due to insufficient number of events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and upper CI not calculable due to insufficient number of events.","groupId":"OG004","lowerLimit":"11.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"OS time was defined as the time from the date of consent signed to the date of death due to any cause. Participants who were alive or lost to follow-up by the end of the study were censored at the date last known to be alive. The Kaplan-Meier method was used to estimate the proportion (%) of subjects without an event at 12 months, as well as their corresponding 95% CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG000","title":"KRAS/NRAS WT"},{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG001","title":"KRAS/NRAS Mut"},{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG002","title":"KRAS/NRAS Missing"},{"description":"Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.","id":"OG003","title":"CXCR4/2 High"},{"description":"Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.","id":"OG004","title":"CXCR4/2 Low"}],"paramType":"MEDIAN","populationDescription":"PP Analysis Set: Included participants who received at least 1 dose of tipifarnib and had a baseline disease assessment and at least 1 post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}